Abstract
Background The Elecsys® Anti-SARS-CoV-2 S immunoassay (Roche Diagnostics International Ltd, Rotkreuz, Switzerland) has been developed for the in vitro quantitative detection of antibodies to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein. We evaluated the performance of this assay using samples from seven sites in Germany, Austria, and Switzerland.
Methods Anonymized frozen, residual serum, or plasma samples from blood donation centers or routine diagnostic testing were used for this study. For specificity and sensitivity analyses, presumed negative samples collected before October 2019 and SARS-CoV-2 PCR-confirmed single or sequential samples were tested, respectively. The performance of the Elecsys Anti-SARS-CoV-2 S immunoassay was also compared with other commercial immunoassays.
Results The overall specificity (n=7880 pre-pandemic samples) and sensitivity (n=240 PCR-positive samples [≥14 days post-PCR]) for the Elecsys Anti-SARS-CoV-2 S immunoassay were 99.95% (95% confidence interval [CI]: 99.87–99.99) and 97.92% (95% CI: 95.21– 99.32), respectively. Compared with seven other immunoassays, the Elecsys Anti-SARS-CoV-2 S assay had comparable or greater specificity and sensitivity. The Elecsys Anti-SARS-CoV-2 S immunoassay had significantly higher specificity compared with the LIAISON® SARS-CoV-2 S1/S2 IgG, ADVIA Centaur® SARS-CoV-2 Total, ARCHITECT SARS-CoV-2 IgG, iFlash-SARS-CoV-2 IgM, and EUROIMMUN Anti-SARS-CoV-2 IgG and IgA assays, and significantly higher sensitivity (≥14 days post-PCR) compared with the ARCHITECT SARS-CoV-2 IgG, iFlash-SARS-CoV-2 IgG and IgM, and EUROIMMUN Anti-SARS-CoV-2 IgG assays.
Conclusion The Elecsys Anti-SARS-CoV-2 S assay demonstrated a robust and favorable performance across samples from multiple European sites, with a very high specificity and sensitivity for the detection of anti-S antibodies.
Competing Interest Statement
Elena Riester and Andreas Ambrosch report grants from Roche Diagnostics, during the conduct of the study and personal fees from Roche Diagnostics (honoraria for lectures), outside the submitted work. Michael Kabesch reports non-financial support from Roche Diagnostics, during the conduct of the study. Christoph Niederhauser, Peter Findeisen and J. Kolja Hegel have nothing to disclose. Florina Langen, Christopher M Rank, and Tina Laengin are employees of Roche Diagnostics GmbH.
Funding Statement
This study was funded by Roche Diagnostics GmbH (Mannheim, Germany).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics statement in the manuscript: These samples were collected and tested in accordance with applicable regulations, including relevant European Union directives and regulations, and the principles of the Declaration of Helsinki. All samples from Augsburg, Heidelberg, Berlin, and Hagen were anonymized. A statement was obtained from the Ethics Committee (EC) of the Landesaerztekammer Bayern confirming that there are no objections to the use of anonymized leftover samples. From the internal EC at the study site in Bern (Switzerland) a waiver was received and from the internal EC at the study site in Innsbruck (Austria) an approval was received. For Regensburg (Germany), EC approvals were already in place, amendments were submitted to notify the EC about Elecsys Anti-SARS-CoV-2 S testing. Details of the IRB/oversight body: 1. Ethics Committee of the Landesaerztekammer Bayern: Waiver was received. 2. Internal Ethics Committee of IRB at Transfusion Interregionale CRS (Switzerland): Waiver was received. 3. Ethics Committee of the Medical University of Innsbruck: Approval was received. 4. Ethics Committee of the University Hospital Regensburg: Approval in place, amendments submitted.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Qualified researchers may request access to individual patient level data through the clinical study data request platform (https://vivli.org/). Further details on Roche's criteria for eligible studies are available here: https://vivli.org/members/ourmembers/. For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here: https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm
